Teladoc Health, Inc. (TDOC)

Teladoc (TDOC) concluded the recent trading session at $8.57, signifying a -4.88% move from its prior day's close.

Teladoc (TDOC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Teladoc (TDOC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Bullish comments from a noted short-seller pushed shares of Teladoc Health (TDOC 6.37%) higher on Friday. The telemedicine services company's stock peaked with a 15.2% jump at 10:20 a.m.

Teladoc Health (TDOC -5.79%) was a pandemic stock, meaning a company whose business was well-positioned to perform well during the worst of the coronavirus outbreak. Since it offers virtual health services, including basic consultation with doctors and therapy services, patients turned to the company in large numbers when government-imposed measures forced them to stay home.

In the latest trading session, Teladoc (TDOC) closed at $8.37, marking a +2.2% move from the previous day.

In the latest trading session, Teladoc (TDOC) closed at $7.87, marking a +2.61% move from the previous day.

In the closing of the recent trading day, Teladoc (TDOC) stood at $7.49, denoting a -3.97% move from the preceding trading day.

Just because a stock has been battered doesn't make it an automatic buy. That's only the case if it can bounce back, and in some cases, there are few good reasons to believe it can.

Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock?

Explore the exciting world of Teladoc (TDOC -0.13%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has acquired Telecare, an innovative, Australian tech-enabled provider of specialist and allied health care via virtual delivery. Telecare operates Australia's leading virtual care clinic and provides software solutions to the healthcare sector.

TDOC posts narrower Q2 loss and trims costs, but shares dip as U.S. revenues and visit volumes decline.

Teladoc Health remains a deep value play at $7, trading at just 5-6x EBITDA, but lacks a clear growth catalyst. Revenue and user metrics are declining across core segments, with BetterHelp and Chronic Care both losing momentum and failing to innovate. Recent acquisitions (UpLift, Catapult Health) have not meaningfully expanded Teladoc's platform or addressed its reliance on basic telehealth connections.

Teladoc's Q2 2025 earnings reaffirm strong free cash flow guidance, with the potential to reach $220 million in the next twelve months. Despite an attractive 7x next year's free cash flow valuation, revenue growth remains stagnant and threatens the bull case. Profitability and an improving balance sheet keep me tepidly bullish, but lack of growth and competitive pressures are major risks.

Teladoc Health, Inc. Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Charles Divita - CEO & Director Mala Murthy - Chief Financial Officer Michael Minchak - Vice President of Investor Relations Conference Call Participants Sarah Elizabeth James - Cantor Fitzgerald & Co., Research Division Charles Rhyee - TD Cowen, Research Division Daniel R. Grosslight - Citigroup Inc., Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division Elizabeth Hammell Anderson - Evercore ISI Institutional Equities, Research Division Jailendra P.